Loading chat...
GA SB481
Bill
Status
Introduced
3/2/2020
Primary Sponsor
Matt Brass
Click for details
AI Summary
- Excludes products approved by the FDA under Section 505 of the federal Food, Drug, and Cosmetic Act from Georgia's definitions of "low THC oil," "marijuana," and "tetrahydrocannabinols," effectively removing them from state controlled substance regulations
- Removes Epidiolex (an FDA-approved CBD-based epilepsy medication) from Georgia's Schedule V controlled substances list by repealing paragraph (1.5) of Code Section 16-13-29
- Amends the Schedule I controlled substances provision to clarify that tetrahydrocannabinols do not include FDA-approved products, aligning state law with federal drug approval determinations
- Sponsored by Senators Brass (28th), Kennedy (18th), and Mullis (53rd) during the 2020 legislative session
Legislative Description
Crimes and Offenses; low THC oil, marijuana, and tetrahydrocannabinols do not include certain federally approved products; provide
Last Action
Senate Read and Referred
3/3/2020
Full Bill Text
No bill text available